mentioned at the top of the show having an impact on a company that has that we've talked a lot about, glaxosmithkline, and then haley. >> just rang the bell. >> just rang the bell, the ceo decided to go on 6:00 in the morning instead of joining us here but that's the story look at what's happening there, because of the worries about zantac remember zantac, you know, basically heartburn medication >> heartburn, yeah >> was on the market for some time, withdrawn from the market since 2019 because of carcinogenic effects there are 2,000 cases filed in the u.s. the first trial begins on the 22nd of august that's why you start to see the focus and result in decline in shares of glaxo and sanofi, but the halhalleon weakness -- >> this is based on one. >> based on one, they could be required to endemify glaxo so i got an analyst saying this is a strong competitor and deep down for haileon walgreens recently in san francisco found guilty they're appealing it >> well, look, this is one of those things, we in our business never really know how to judge what a judge would do. >> no. >> i always like to regard i